Cost-effectiveness of personalised screening for colorectal cancer based on polygenic risk and family history.
There is growing evidence for personalising colorectal cancer (CRC) screening based on risk factors. We compared the cost-effectiveness of personalised CRC screening based on polygenic risk and family history to uniform screening. Using the MISCAN-Colon model we simulated a cohort of 100 million 40-year-olds, offering them uniform or personalised screening. Individuals were categorised based on polygenic risk and family history of CRC. We varied screening strategies by start age, interval and test and estimated costs and quality-adjusted life years (QALYs). In our analysis we: 1) assessed the cost-effectiveness of uniform screening; 2) developed personalised screening scenarios based on optimal screening strategies by risk group; 3) compared the cost-effectiveness of both. At a willingness-to-pay threshold of $50,000/QALY, the optimal uniform screening scenario was annual faecal immunochemical testing (FIT) from 50-74 years while for personalised screening the optimal screening scenario consisted of annual and biennial FIT screening except for those at highest risk who were offered 5-yearly colonoscopy from age 50. Although these scenarios gained the same number of QALYs (17,887), personalised screening was not cost effective, costing an additional $428,953 due to costs associated with determining risk (assumed to be $240 per person). Personalised screening was cost effective when these costs were less than ~$48. Uniform CRC screening currently appears more cost effective than personalised screening based on polygenic risk and family history. However, cost-effectiveness is highly dependent on the cost of determining risk. Personalised screening could become increasingly viable as costs for determining risk decrease.